(Q35666531)

English

The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

scientific article published on 18 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

multicenter clinical trial

0 references

multiple sclerosis

0 references

1

object named as

Tjalf Ziemssen

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Raimar Kern

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Christian Cornelissen

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

18 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

93

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

copyright license

Creative Commons Attribution 4.0 International

18 June 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Fingolimod for the treatment of neurological diseases-state of play and future perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Fingolimod-associated macular edema: incidence, detection, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

The changing face of multiple sclerosis clinical trial populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

[Projection of the number of multiple sclerosis patients in Germany]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

27 July 2018

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

25 September 2018

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

25 September 2018

The development of patient-reported outcome indices for multiple sclerosis (PRIMUS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

25 September 2018

Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4472406

25 September 2018

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Multiple sclerosis management system 3D. Moving from documentation towards management of patients]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12883-015-0342-0

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35666531&oldid=2197595977"